Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (3)
P 2 (1)

Trial Status

Recruiting4
Not Yet Recruiting2
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07753824Phase 2Not Yet Recruiting

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

NCT07587268Recruiting

Molecular Profiling for Risk Stratification in Appendiceal Cancer

NCT07658196Phase 1Not Yet Recruiting

TLR9 Immunotherapy for Peritoneal Carcinomatosis

NCT05947838Not ApplicableRecruitingPrimary

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

NCT06399757Phase 1Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT05734430Recruiting

Genetics of Appendix Cancer Study

NCT04665921Phase 1Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Showing all 7 trials

Research Network

Activity Timeline